[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HN2011002022A - Composicion farmaceutica solida que comprende amlodipina y losartan - Google Patents

Composicion farmaceutica solida que comprende amlodipina y losartan

Info

Publication number
HN2011002022A
HN2011002022A HN2011002022A HN2011002022A HN2011002022A HN 2011002022 A HN2011002022 A HN 2011002022A HN 2011002022 A HN2011002022 A HN 2011002022A HN 2011002022 A HN2011002022 A HN 2011002022A HN 2011002022 A HN2011002022 A HN 2011002022A
Authority
HN
Honduras
Prior art keywords
losartan
amlodipina
pharmaceutical composition
solid pharmaceutical
composition including
Prior art date
Application number
HN2011002022A
Other languages
English (en)
Inventor
Park Jae Hyun
Kim Kyeong Soo
Yim Ho Taek
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011002022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of HN2011002022A publication Critical patent/HN2011002022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA A UNA COMPOSICION FARMACEUTICA SOLIDA PARA PREVENIR O TRATAR DESORDENES CARDIOVASCULARES QUE COMPRENDE AMLODIPINA Y LOSARTAN COMO INGREDIENTES ACTIVOS, Y UN DESINTEGRANTE EL CUAL ES UNA MEZCLA DE POR LO MENOS 2 COMPONENTES SELECCIONADOS DEL GRUPO CONSISTENTE DE GLICOLATO DE ALMIDON DE SODIO,SODIO DE CRUCE DE CARMELOSA Y CRUCE DE PROVIDONA, LO CUAL SU ALTO Y ESTABLE NIVEL DE AMLODIPINA Y LOSARTAN.
HN2011002022A 2009-01-23 2011-07-21 Composicion farmaceutica solida que comprende amlodipina y losartan HN2011002022A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20090005840 2009-01-23

Publications (1)

Publication Number Publication Date
HN2011002022A true HN2011002022A (es) 2014-02-03

Family

ID=42306870

Family Applications (2)

Application Number Title Priority Date Filing Date
HN2011002022A HN2011002022A (es) 2009-01-23 2011-07-21 Composicion farmaceutica solida que comprende amlodipina y losartan
HN2011002020A HN2011002020A (es) 2009-01-23 2011-07-21 Composicion farmaceutica solida que comprende amlodipina y losartan y proceso para la produccion de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
HN2011002020A HN2011002020A (es) 2009-01-23 2011-07-21 Composicion farmaceutica solida que comprende amlodipina y losartan y proceso para la produccion de la misma

Country Status (33)

Country Link
US (3) US9161933B2 (es)
EP (3) EP2413931B1 (es)
JP (3) JP5658172B2 (es)
KR (2) KR101232296B1 (es)
CN (4) CN102292085B (es)
AR (3) AR070897A1 (es)
AU (3) AU2009338267B2 (es)
BR (3) BRPI0924136B8 (es)
CA (3) CA2749903C (es)
CL (1) CL2011001781A1 (es)
CO (3) CO6361905A2 (es)
CR (3) CR20110448A (es)
DO (3) DOP2011000231A (es)
EA (3) EA020103B1 (es)
EC (1) ECSP11011253A (es)
ES (3) ES2580777T3 (es)
HK (1) HK1163539A1 (es)
HN (2) HN2011002022A (es)
IL (3) IL214145A0 (es)
JO (2) JO2981B1 (es)
MA (3) MA33056B1 (es)
MX (3) MX349221B (es)
MY (3) MY173823A (es)
NI (3) NI201100145A (es)
NZ (3) NZ594738A (es)
PE (4) PE20100559A1 (es)
SA (1) SA110310070B1 (es)
SG (3) SG173044A1 (es)
TW (3) TWI404534B (es)
UA (3) UA102721C2 (es)
UY (2) UY32389A (es)
WO (3) WO2010085014A1 (es)
ZA (3) ZA201106160B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349221B (es) 2009-01-23 2017-07-19 Hanmi Science Co Ltd * Composicion farmaceutica solida que comprende amlodipina y losartan y procesos para producir la misma.
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
CN112933093A (zh) * 2015-06-30 2021-06-11 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR20210074428A (ko) 2019-12-11 2021-06-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR20210152943A (ko) 2020-06-09 2021-12-16 한미약품 주식회사 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0736021A4 (en) 1993-12-23 1997-04-02 Merck & Co Inc LOSARTANE POLYMORPHS AND PROCESS FOR THE PREPARATION OF FORM II OF LOSARTANE
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
AU2001279284A1 (en) * 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001284413A1 (en) 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
CA2463758A1 (en) 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US20060128763A1 (en) 2003-01-27 2006-06-15 Moon Young H Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
EP1648357A2 (en) * 2003-07-18 2006-04-26 Pneu Medex Inc. Fluid operated actuators and pneumatic unloading orthoses
SI1653950T1 (sl) 2003-07-31 2008-06-30 Nicox Sa Nitrooksi derivati losartana, valsatana, kandesartana, telmisartana, eprosartana in olmesartana kotblokatorji receptorja angiotenzina-II za zdravljenje kardiovaskularnih bolezni
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
WO2006048208A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007001065A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
JP5110697B2 (ja) 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
AU2006311723A1 (en) 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
MY149306A (en) * 2005-12-22 2013-08-30 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023958A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
MX349221B (es) 2009-01-23 2017-07-19 Hanmi Science Co Ltd * Composicion farmaceutica solida que comprende amlodipina y losartan y procesos para producir la misma.

Also Published As

Publication number Publication date
ZA201106160B (en) 2012-10-31
PE20140978A1 (es) 2014-08-16
CO6361915A2 (es) 2012-01-20
UY32388A (es) 2010-02-26
EA201170958A1 (ru) 2012-01-30
BRPI0924136A2 (pt) 2017-06-13
CN102292085A (zh) 2011-12-21
KR20100086913A (ko) 2010-08-02
EP2413931A4 (en) 2012-08-08
NZ594739A (en) 2013-11-29
MA33056B1 (fr) 2012-02-01
UA102721C2 (uk) 2013-08-12
MX2011006008A (es) 2011-06-28
SG173046A1 (en) 2011-08-29
NZ594738A (en) 2013-11-29
DOP2011000229A (es) 2011-10-15
EP2413931B1 (en) 2016-06-01
BRPI0924135A2 (pt) 2016-02-10
EP2391365A4 (en) 2012-07-25
AU2009338267A1 (en) 2011-09-15
CN102292084A (zh) 2011-12-21
PE20120428A1 (es) 2012-05-17
EA021763B1 (ru) 2015-08-31
US8673945B2 (en) 2014-03-18
IL214145A0 (en) 2011-08-31
JP5658172B2 (ja) 2015-01-21
AU2009338251B2 (en) 2014-03-13
UA105203C2 (ru) 2014-04-25
EP2413931A1 (en) 2012-02-08
NI201100144A (es) 2012-11-06
AR075028A1 (es) 2011-03-02
CA2749957A1 (en) 2010-07-29
CR20110448A (es) 2011-11-10
HK1163539A1 (en) 2012-09-14
US20110251245A1 (en) 2011-10-13
CR20110449A (es) 2011-11-10
BRPI0924136B1 (pt) 2019-10-15
CN102292070A (zh) 2011-12-21
EP2391348B1 (en) 2014-08-27
EP2391365A2 (en) 2011-12-07
EP2391348A1 (en) 2011-12-07
JO3328B1 (ar) 2019-03-13
CN105998017A (zh) 2016-10-12
ZA201106162B (en) 2012-10-31
EP2391348A4 (en) 2012-07-25
MX345956B (es) 2017-02-28
KR20100086921A (ko) 2010-08-02
US20110245301A1 (en) 2011-10-06
BRPI0924136A8 (pt) 2017-10-03
JP5660544B2 (ja) 2015-01-28
CA2749903A1 (en) 2010-07-29
MY150974A (en) 2014-03-31
ZA201106161B (en) 2012-10-31
ES2505116T3 (es) 2014-10-09
SA110310070B1 (ar) 2014-09-02
ES2580777T8 (es) 2016-09-22
AR070897A1 (es) 2010-05-12
TW201031404A (en) 2010-09-01
NZ594740A (en) 2013-11-29
AU2009338267B2 (en) 2014-09-18
WO2010085047A3 (en) 2010-11-04
ES2580777T3 (es) 2016-08-26
CA2749955A1 (en) 2010-07-29
US20110245302A1 (en) 2011-10-06
DOP2011000231A (es) 2011-10-15
MX345868B (es) 2017-02-21
TWI395583B (zh) 2013-05-11
CO6361914A2 (es) 2012-01-20
SG173044A1 (en) 2011-08-29
IL214147A (en) 2016-08-31
US9161933B2 (en) 2015-10-20
EA201170959A1 (ru) 2011-12-30
MX349221B (es) 2017-07-19
AU2009338267A2 (en) 2011-09-29
UY32389A (es) 2010-02-26
US8673944B2 (en) 2014-03-18
MX2011006061A (es) 2011-06-24
WO2010085014A1 (en) 2010-07-29
EP2391365B1 (en) 2014-11-26
EA019471B1 (ru) 2014-03-31
DOP2011000230A (es) 2011-10-15
ECSP11011253A (es) 2011-09-30
CL2011001781A1 (es) 2012-03-23
ES2526606T3 (es) 2015-01-13
AR075027A1 (es) 2011-03-02
MA33058B1 (fr) 2012-02-01
CA2749957C (en) 2016-07-26
JP2012515768A (ja) 2012-07-12
MY151550A (en) 2014-06-13
AU2009338251A1 (en) 2011-09-15
CO6361905A2 (es) 2012-01-20
AU2009338280A1 (en) 2011-09-15
CA2749955C (en) 2016-07-26
JP2012515770A (ja) 2012-07-12
CR20110450A (es) 2011-11-10
EA201170960A1 (ru) 2012-01-30
CA2749903C (en) 2016-09-06
JP2012515767A (ja) 2012-07-12
JP5466716B2 (ja) 2014-04-09
WO2010085047A2 (en) 2010-07-29
WO2010085027A1 (en) 2010-07-29
CN102292084B (zh) 2014-01-29
PE20100559A1 (es) 2010-09-12
BRPI0924137A2 (pt) 2019-09-24
SG173045A1 (en) 2011-08-29
AU2009338280B2 (en) 2014-05-01
UA102720C2 (ru) 2013-08-12
IL214147A0 (en) 2011-08-31
MA33057B1 (fr) 2012-02-01
NI201100145A (es) 2012-08-17
IL214146A0 (en) 2011-08-31
KR101232296B1 (ko) 2013-02-13
JO2981B1 (ar) 2016-09-05
PE20100739A1 (es) 2010-11-19
HN2011002020A (es) 2014-02-03
NI201100143A (es) 2012-08-17
MY173823A (en) 2020-02-24
TW201028151A (en) 2010-08-01
TWI404534B (zh) 2013-08-11
EA020103B1 (ru) 2014-08-29
MX2011006009A (es) 2011-06-28
BRPI0924136B8 (pt) 2021-05-25
KR101160151B1 (ko) 2012-06-27
CN102292085B (zh) 2017-01-18

Similar Documents

Publication Publication Date Title
HN2011002022A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
PA8842101A1 (es) Heteroarilos sustituidos
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20110209A (es) Composición farmacéutica sólida
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
HN2011000072A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
GT201000062A (es) Composiciones farmacéuticas liofilizadas
ECSP11011251A (es) Composición farmacéutica sólida que comprende amlodipina y losartan con estabilidad mejorada.
ECSP11011252A (es) Composición farmacéutica sólida que contiene amlopidina y losartán, así como el proceso para producir la misma.
UY31030A1 (es) Compuestos
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.
UY30000A1 (es) Compuestos aromaticos sustituidos, composiciones farmaceuticas conteniendolos, procesos de preparación y aplicaciones.
UY29501A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización